10. 無論男女都會因HPV持續感染而導致相關疾病
Disclaimer: GARDASIL®/GARDASIL 9 ® are not indicated for the prevention of HPV-related penile or oropharyngeal precancer or cancers or anal cancers.
aAccurate global incidence estimates for high- and low-grade cervical dysplasias are not available. Incidence rates may vary geographically and not all lesions are diagnosed or reported, notably in countries
without organized screening programs.
bEstimated gender ratio of genital warts: 54% males, 46% females.
cData are from 1995 and may not be representative of current prevalence. More recent data are not available.
Global Estimated Annual New HPV-Related Disease Cases in Males and Females
Penile cancer1,2
Genital warts4–6,b,c
Oropharyngeal cancer3
Anal cancer3
Cervical dysplasiaa
Vulvar & vaginal cancer1,2
Cervical cancer1
Genital warts4–6,b,c
Oropharyngeal cancer3
Anal cancer3
11,200
18,200
528,000
17,300,000 14,400,000
Millions of cases
4,40017,000
11,000 13,000
陰莖癌
口咽癌
肛門癌
尖形濕疣(菜花)
子宮頸癌
外陰癌/陰道癌
子宮頸癌前病變
11. 北美洲 歐洲 亞洲(台灣)
HPV16+18=78% HPV16+18=73.5% HPV16+18=58.7%
Others=HPV31,33,45,52,58…占
約41.3%
GM Clifford et al., British Journal of Cancer (2003) 88(1), 63 – 73
13. HPV16 和 HPV58 造成
較高罹患子宮頸侵襲癌和子宮頸癌前病變的風險
HC Chen et al., Persistence of Type-Specific Human Papillomavirus Infection and Increased Long-term Risk of Cervical Cancer; 2011, DOI: 10.1093/jnci/djr283
Years after the baseline visitNumber at risk
22. WHO 宣布要消滅子宮頸癌
First Second Third
WHO Director-General's Office . Retrieved from 2019/03/26 https://www.who.int/dg/speeches/2018/UNGA-cervical-cancer/en/(2019/3/26)
A World free of cervical cancer
HPV
Vaccination
HPV
Screen
Diagnosis &
Treatment
World Health Organization (WHO)=世界衛生組織
Human papillomavirus (HPV)=人類乳突病毒
29. 九價 HPV 疫苗 與四價疫苗比較,
25 23
1
2
35
657
3
110
1
10
100
1000
Related to
HPV 6, 11, 16, or 18
Related to
HPV 31, 33, 45, 52, or 58
Related to
HPV 6, 11, 16, or 18
Related to
HPV 31, 33, 45, 52, or 58
n=5812 n=5830 n=5941 n=5955
12 months’ persistent infection
n=5824 n=5832 n=5949 n=5943
CIN (any grade)
RelatedCases
Per-Protocol Efficacy Population 長期追蹤已達 6 年
Lancet. 2017 Nov 11;390(10108):2143-2159
4vHPV vaccine
9vHPV vaccine
28.5%
Reduction
(95% CI: -22.9, 57.7)
96.7%
Reduction
(95% CI: 95.1, 97.9)
66.6%
Reduction
(95% CI: -203.0, 98.7)
98.2%
Reduction
(95% CI: 93.7, 99.7)
在預防與第31、33、45、52 和 58 型 HPV 病毒相關之
持續感染/CIN (any grade) 上具有至少 96% 的預防效果
This randomized, double-blind, controlled, dose-ranging, efficacy, immunogenicity, and safety study of 9vHPV was carried out at 105 sites located in 18 countries. Women aged 16-26 who were
generally healthy, had no history of abnormal cervical cytology were included
30. 九價 HPV 疫苗 與四價疫苗比較,
CIN 3 or worse EGLs 外陰部疣
0 0
5
2
1
7
9
26
0
5
10
15
20
25
30
RelatedCases
Related to
HPV 6, 11, 16, or 18
Related to
HPV 31, 33, 45, 52, or 58
Related to
HPV 6, 11, 16, or 18
Related to
HPV 31, 33, 45, 52, or 58
n=5824 n=5832 n=5949 n=5943 n=5876 n=5893 n=6009 n=6012
4vHPV vaccine
9vHPV vaccine
44.3%
Reduction
(95% CI: -70.0, 81.9)
92.3%
Reduction
(95% CI: 72.4, 98.7)100%
Reduction
(95% CI: -∞, 100)
100%
Reduction
(95% CI: 39.4, 100)
Per-Protocol Efficacy Population 長期追蹤已達 6 年
在預防與 31、33、45、52 和 58 型 HPV 病毒相關之
EGLs (external genital warts) / CIN 3+上具有至少 92% 的預防效果
This randomized, double-blind, controlled, dose-ranging, efficacy, immunogenicity, and safety study of 9vHPV was carried out at 105 sites located in 18 countries. Women aged 16-26 who were
generally healthy, had no history of abnormal cervical cytology were included
Lancet. 2017 Nov 11;390(10108):2143-2159
40. HPV vaccine is included in the National Immunization Program (NIP) in many
countries and is routinely provided via school-based programs for girls and boys
12–13 years of age.
Those who receive the vaccine prior to commencement of sexual activity will gain
the most benefit from HPV vaccine.
世界衛生組織公報: 建議女性接種HPV疫苗與子宮頸抹片
41. Summary of efficacy in males
四價HPV疫苗對於男性(16-26歲)的保護效果
Analysis of Efficacy of 4vHPV vaccine in the PPE* Population for Vaccine HPV Types2,3
Endpoints
4vHPV Placebo Control
% Efficacy
(95% CI)N
Number of
cases
N
Number of
cases
16- Through 26-Year-Old Boys and Men
HPV 6-, 11-, 16-, or 18-related
Persistent Infection**
1390 15 1400 101
85.6
(73.4, 92.2)
External HPV 6-, 11-, 16-, or 18-related Genital
Lesions**
1394 3 1404 32
90.6
(70.1, 98.2)
HPV 6-, 11-, 16-, or 18-related Genital Warts** 1394 3 1404 28
89.3
(65.3, 97.9)
HPV 6-, 11-, 16-, or 18-related PIN 1/2/3** 1394 0 1404 4
100.0
(-52.1, 100.0)
HPV 6-, 11-, 16-, or 18-related AIN 2/3*** 194 3 208 13
74.9
(8.8, 95.4)
*The PPE population consisted of individuals who received all 3 vaccinations of 4vHPV vaccine within 1 year of enrolment, did not have major deviations
from the study protocol, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through
1 month postdose 3 (Month 7).
Follow up time; **Median duration of follow-up 2.4 years; ***Median duration of follow-up was 2.15 years; External Genital
Lesions = External genital warts; penile/perianal/perineal intraepithelial neoplasia (PIN); penile, perianal, or perineal cancer4; N=Number of individuals
with at least 1 follow-up visit after Month 7; CI=Confidence Interval.
1. Castellsague et al. Vaccine 2015; ;33(48):6892-901
2. Gardasil 9, Summary of Product Characteristics, February 2015
3. Supplement for Giuliano AR et al. N Engl J Med. 2011;364(5):401-11
4. Giuliano AR et al. N Eng J Med 2011;364:401-11.
51. HPV疫苗接種 應納入國家政策(NIP)
2015 WHO全球疫苗安全諮詢委員會關於HPV疫苗安全性聲明
GACVS statement on safety of HPV vaccines 17 December 2015
WHO GACVS - Statement on Safety of HPV vaccines,17 December 2015, Retrieved from
https://www.who.int/vaccine_safety/committee/topics/hpv/statement_Dec_2015/en/ (May ,18,2019)
2億劑
自2006年初首次獲得許可以來,全球已經接種了2億多劑
HPV疫苗。 WHO建議將HPV疫苗納入國家免疫規劃
(NIP)。
迄今為止,尚未發現任何安全問題會改變其疫苗使用建
議。
Human Papillomaviruses(HPV)=人類乳突病毒
World Health Organization (WHO) 世界衛生組織
national immunization programme(NIP)=國家政策公費施打
Global Advisory Committee for Vaccine Safety (GACVS)=全球疫苗安全諮詢委員會
在日本,有一些人接種疫苗發生慢性疼痛和其他症狀,
導致國家暫停主動推薦NIP。 國家專家委員會對臨床數據的回顧
得出結論,認為症狀與疫苗無關, 但尚無法恢復HPV疫苗接種共
識。GACVS指出,基於證據不足的政治決策,導致女性沒有有效
且安全的疫苗使用,可能造成真正的傷害。
WHO
World Health
Organization
52. Weekly epidemiological record , Retrieved from: http://www.who.int/wer (2019/5/20)
national immunization programme(NIP)=國家政策公費施打
World Health Organization (WHO) 世界衛生組織
Global Advisory Committee for Vaccine Safety (GACVS)=全球疫苗安全諮詢委員會
HPV疫苗接種 應納入國家政策(NIP)
2017 WHO全球疫苗安全諮詢委員會關於HPV疫苗安全性聲明
GACVS審查來自美國,澳大利亞,日本以及其他國家的上市後
後監測數據,所有數據來源顯示目前現有3種HPV疫苗安全性仍是
可放心,現有證據並未表明使用HPV疫苗存在任何安全問題。
71國家
雖然有個案報告關於疫苗施打後的一些慢性疾病發生,包括自
身免疫性疾病,但一項關於上市後後安全性監測研究表明,HPV疫
苗與這些病症之間沒有關聯。HPV疫苗不會增加急性多發性神經
炎,或稱格林-巴利症候群(Guillain- Barré syndrome)的風險。
截至2017年3月,已經有71個國家將HPV疫苗已納入女
性NIP,有11個國家將男性也納入NIP
WHO
World Health
Organization
53. aSubjects who received at least 1 dose of 9vHPV vaccine and had safety follow-up. bResults are pooled safety data from subjects 9 to 26 years of age who
received 9vHPV vaccine in studies Protocol 001, 002, 003, 005, 006, 007, and 009.
83.2
36.1
30.8
4 1.6
13.2
6.1
3.2 2.3 1.9
0
20
40
60
80
100
Pain Swelling Erythema Pruritus Bruising Headache Pyrexia Nausea Dizziness Fatigue
任何一劑疫苗後1-5天
注射部位 AE b
PercentageofSubjects
Injection-Site AEs and Vaccine-Related Systemic AEs Reported
at a Frequency of ≥1%
綜合所有臨床試驗研究安全性數據 受試者族群9-26歲
• 綜合7個9-26歲的15,776名Gardasil 9受試者安全性資料。(Protocol 001, 002, 003, 005, 006, 007,
and 009).a
• 最常見的注射部位不良反應為疼痛(83.2%),最常見的全身不良反應為頭痛(13.2%)
• 大部分注射部位不良反應為輕至中度
疼痛 腫脹 紅斑 搔癢 瘀血 頭痛 發燒 噁心 頭暈 疲勞
任何一劑疫苗後1-15天
疫苗相關性全身性AE b
Gardasil 9 安全性
58. HPV 6
(7,905 bp***)
E6
Several Factors May Minimize/
Prevent HPV Exposure to the Immune
System
No blood-borne phase of infection1
» No viremia
Limited and delayed expression of late viral capsid proteins1,2
HPV does not lyse keratinocytes.1
» No release of pro-inflammatory cytokines1
» Little tissue destruction associated with HPV3
E6 and E7 suppress interferon signaling necessary for cell-mediated
immune response.1
No activation of Antigen Presenting Cell (APCs)1
60. Accessed on 4 July 2019.
二價疫苗 Gardasil Gardasil 9
疫苗所含的
HPV型別
16 V V V
18 V V V
6 V V
11 V V
31 V
33 V
45 V
52 V
58 V
預防
子宮頸癌 V V V
外陰癌癌前病變 V (輕度) V (中重度) V (中重度)
陰道癌癌前病變 V (輕度) V (中重度) V (中重度)
生殖器疣 V V
適用對象
男性 9-26歲 9-26 歲
女性 >9歲以上 9-45歲 9-26 歲
61. GARDASIL®
9 Q&A
2 0 1 9 . 1 0 . 2 2
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) helps protect
individuals ages 9 to 26 against the following diseases caused by 9 types of HPV: cervical,
vaginal, and vulvar cancers in females, anal cancer and genital warts in both males and females.